tacernol
egis pharmaceuticals plc - atorvastatinas/perindoprilio argininas - kietosios kapsulės - 20 mg/10 mg; 10 mg/10 mg; 40 mg/5 mg; 20 mg/5 mg; 10 mg/5 mg; 40 mg/10 mg - atorvastatin and perindopril
torvacard
zentiva k.s. - atorvastatinas - plėvele dengtos tabletės - 10 mg; 20 mg - atorvastatin
kabiven peripheral
fresenius kabi ab - išgrynintas sojų aliejus/gliukozė/alaninas/argininas/asparto rūgštis/glutamo rūgštis/glicinas/histidinas/izoleucinas/leucinas/lizinas/metioninas/fenilalaninas/prolinas/serinas/treoninas/triptofanas/tirozinas/valinas/kalcio chloridas/natrio glicerofosfatas/magnio sulfatas/kalio chloridas/natrio acetatas - infuzinė emulsija - 51 g/97 g/4,8 g/3,4 g/1 g/1,7 g/2,4 g/2 g/1,7 g/2,4 g/2,7 g/1,7 g/2,4 g/2 g/1,4 g/1,7 g/0,57 g/0,069 g/2,2 g/0,22 g/1,5 g/0,48 g/1,8 g/1,5 g/1440 ml; 51 g/97 g/4,8 g/3,4 g/1 g/1,7 g/2,4 g/2 g/1,7 g/2,4 g/2,7 g/1,7 g/2,4 g/2 g/1,4 g/1,7 g/0,57 g/0,069 g/2,2 g/0,22 g/1,5 g/0,48 g - combinations
water for injections csl behring
csl behring gmbh - injekcinis vanduo - tirpiklis parenteriniam vartojimui - 2-50 ml - solvents and diluting agents, incl. irrigating solutions
progesterone besins
besins healthcare ireland limited - progesteronas - makšties minkštosios kapsulės - 200 mg - progesterone
human albumin csl behring
csl behring gmbh - Žmogaus albuminas - infuzinis tirpalas - 200 g/l - albumin
human c1-esterase inhibitor csl behring
csl behring gmbh - Žmogaus c1-esterazės inhibitorius - milteliai ir tirpiklis injekciniam ar infuziniam tirpalui - 500 tv - c1-inhibitor, plasma derived
human c1-esterase inhibitor csl behring
csl behring gmbh - Žmogaus c1-esterazės inhibitorius - milteliai ir tirpiklis injekciniam tirpalui - 1500 tv - c1-inhibitor, plasma derived
fatrovax rhd
fatro s.p.a - rabbit hemorrhagic disease virus 2 vp1ab, rabbit hemorrhagic disease virus vp1a - immunologicals už kiškinių (leporidae) - triušiai - for active immunisation of rabbits from the age of 28 days to reduce mortality, infection, clinical signs and organ lesions of rabbit haemorrhagic disease caused by rhdv1 and rhdv2.
rybrevant
janssen-cilag international n.v. - amivantamab - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.